Clinical trials: Cannabidiol
Epilepsy, Dravet Syndrome
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
- Trial name
- NCT02091375
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Jazz Pharmaceuticals
Lennox-Gastaut Syndrome
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).
- Trial name
- EPI-COG (NCT04133480)
- Testing
- GWP42003-P
- Sponsor
- Jazz Pharmaceuticals
Infantile Spasms
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The open-label extension phase only will be described in this record.
- Trial name
- NCT02954887
- Testing
- GWP42003-P
- Where
- 7 sites in United States, Poland
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Spontaneous Urticaria
Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients
Each patient will commence the study with a one month run-in period in which he/she will be administered individual patient Standard of Care :anti-histamines and steroids as needed plus placebo (olive oil).
- Trial name
- NCT04439955
- Testing
- CBD
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Stero Biotechs Ltd.
Fatty Liver
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
- Trial name
- NCT01284634
- Testing
- GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GW Research Ltd
Fragile X Syndrome
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome…
- Trial name
- CONNECT-FX (NCT03614663)
- Testing
- ZYN002 - Cannabidiol Transdermal Gel
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Zynerba Pharmaceuticals, Inc.
Autoimmune Hepatitis
A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with…
- Trial name
- NCT04129489
- Testing
- Cannabidiol
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Stero Biotechs Ltd.
Epilepsy
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02607904
- Testing
- GWP42003-P
- Where
- 5 sites in Netherlands, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Jazz Pharmaceuticals
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Fibromyalgia
CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)
Fibromyalgia is considered a chronic pain syndrome, non-inflammatory, of unknown etiology, which manifests itself in the musculoskeletal system in up to 2.5% of the general population, predominantly in females, mainly between 35…
- Trial name
- NCT05283161
- Testing
- cannabidiol and tetrahydrocannabinol
- Volunteers
- 40 people
- Sponsor
- FG Brasil LTDA
Osteoarthritis, Knee
Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee
The purpose of the study is to evaluate the efficacy of PG-OA-10CN and PG-OA-5TH tablets as a better pain reliever in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo.
- Trial name
- NCT04992962
- Testing
- CBD/CBN, CBD/THC
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Pure Green
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Seizures
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
This is a multi-center, non-interventional and prospective study of patients receiving Epidyolex as part of standard clinical practice in France.
- Trial name
- OPERA (NCT05772429)
- Testing
- Epidiolex
- Where
- 29 sites in France
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Diabetic Neuropathies
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
- Trial name
- NCT04088929
- Testing
- CBD
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Pure Green
Insomnia
Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia is a disorder in which people have inadequate or poor-quality sleep due to a number of factors, such as difficulty falling asleep, waking up frequently during the night with difficulty returning to sleep, waking up too…
- Trial name
- NCT05233761
- Testing
- Defined CBD
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Defined Research
Pain, Sleep Disturbance
Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting
A randomized, open-label study of commercially available, orally ingestible, Cannabidiol (CBD) products used in the real-world setting for pain, sleep, and anxiety.
- Conditions
- Pain, Sleep Disturbance, Anxiety
- Trial name
- RWE-ACES (NCT05003882)
- Testing
- Commercially available, orally ingestible CBD product
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Lennox Gastaut Syndrome, Dravet Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- EpiTALY (NCT05485831)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- 18 sites in Italy
- Volunteers
- 111 people
- Sponsor
- Jazz Pharmaceuticals
Lennox-Gastaut Syndrome
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
This Phase 3 trial will enroll participants diagnosed with Lennox-Gastaut Syndrome (LGS) who are still experiencing at least 4 motor seizures involving the trunk or extremities per week, despite ongoing treatment with up to 3…
- Trial name
- NCT02318537
- Testing
- Cannabidiol Oral Solution
- Sponsor
- INSYS Therapeutics Inc
Epilepsy Intractable
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.
- Trial name
- NCT02987114
- Testing
- PLT101
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- PhytoTech Therapeutics, Ltd.